摘要
目的探讨三氧化二砷(As2O3)联合IFNα-2a治疗人多发性骨髓瘤(MM)的可行性。方法将人MM细胞系U266细胞株随机分为4组,空白对照组不行特殊处理,As2O3组加入As2O3,IFNα-2a组加入IFNα-2a,As2O3+IFNα-2a组同时加入As2O3及IFNα-2a。孵育48h后用双标记流式细胞术检测细胞凋亡率,用流式细胞仪检测细胞肿瘤坏死因子相关凋亡诱导配体(TRAIL)及其受体表达。结果As2O3+IFNα-2a组细胞凋亡率、TRAIL及其受体表达均显著高于其他三组(P<0.05),空白对照组TRAIL及其受体表达均显著低于其他三组(P<0.05)。结论As2O3及IFNα-2a均可上调TRAIL及其受体表达,促进U266细胞凋亡,且两者有协同作用;此为临床治疗MM提供了新的思路。
Objective To investigate the feasibility of combination of arsenic trioxide （ As2O3 ） and interferon α-2a in the treatment of multiple myeloma（MM）. Methods U266 cells were randomly divided into four groups , three of Milch were treated with IFNα-2a and（or） As2O3 for 48 hours. The rate of apoptosis was assessed by Annexin-V-FITC and PI staining. The expression of TRAIL and its receptors DR4, DR5 were detected by flow cytometry. Results The rate of apoptosis ,the expression of TRAIL and its receptor in As2O3 ＋ IFNα-2a group were higher than those in the other three groups（P 〈 0.05 ）. The expression of TRAIL and its receptor in the control group was lower than that in the other three groups（ P 〈 0.05 ）. Conclusion Both As203 and IFNα-2a cart up-regulate the expression of TRAIL and its receptor,induce U266 cell apoptosis. This study provides new way for the treatment of MM.
出处
《山东医药》
CAS
北大核心
2009年第11期13-14,共2页
Shandong Medical Journal
